ÂÜÀòÂÒÂ×

Ethan Shin is a seasoned professional in the biotechnology and pharmaceuticals industry, currently serving as a Board Observer for Bright Peak Therapeutics, Odyssey Therapeutics, and Hyku Biosciences. Since June 2018, Ethan has held the position of Managing Director at KB Investment and the RMG-KB BioAccess Fund, further showcasing expertise in investment management. Previous roles include Director on the Board of Directors for BioProtect Ltd, S&E Bio, and CellinCells, alongside experience as a Board Observer for Arvelle Therapeutics and Director at Bridge Biotherapeutics, Inc. Ethan holds a Doctor of Pharmacy (PharmD) from the University of Illinois Chicago and a Bachelor of Science (BS) in Chemistry from Emory University.